Epeius Granted Patent for Gene Delivery System
Posted on: Tuesday, 25 March 2008, 12:00 CDT
Epeius Biotechnologies has announced the issue of US patent for targeted gene delivery in vivo.
This patent provides additional intellectual property protection for the platform of highly advanced biotechnologies embodied in the company's leading anti-cancer agent, Rexin-G. Administered clinically by simple intravenous infusion, the Epeius tumor-targeted gene delivery system enables Rexin-G to seek out and accumulate selectively in cancerous tissues and remote metastatic tumor nodules that have spread throughout the body. Rexin-G delivers it tumor-killing payload precisely where it is needed most, by targeting cancer from the inside.
The FDA has granted orphan drug status to Rexin-G based on its performance as a single therapeutic agent in treating chemotherapy refractory pancreatic cancer. Currently, Rexin-G is being tested as a single therapeutic agent in three separate US Phase I/II Trials for recurrent or metastatic cancers of the breast or pancreas and for bone and soft tissue sarcoma respectively.
Source: Datamonitor
Related Articles
- Loss Of Tumor Supressor Gene Essential To Transforming Benign Nerve Tumors Into Cancers
- A Potent And Selective Anti-tumor Agent On Human Gastric Cancer
- Epeius Biotechnologies' Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted By National Cancer Institute Journal
- ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
- Samaritan Licenses Tumor Inhibiting Cancer Drugs That Also Distinguish Cancerous Tumors to Improve On Chemotherapy
- Samaritan Exclusively Licenses Innovative Blood Diagnostic to Uncover Whether Breast Tumor is Cancer
- Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
- A novel mechanism of action for anti-tumor agent, CA4P
- Small Tumors Boost Cancer Survival
- NeoPharm: Brain Tumor Agent May Struggle to Overtake Temodar
 |
 |
User Comments (0)
RSS Feeds